Acceptance and Commitment Therapy (ACT) for rumination and worry in individuals with anxiety and depression: A randomized control trial

Not Applicable

Recruiting

• Conditions: Major depressive disorder; Dysthymic disorder; Anxiety disorders excluding Obsessive Compulsive Disorder and Post-Traumatic Stress Disorder; Mental Health - Depression; Mental Health - Anxiety

• Registration Number: ACTRN12611000240943
• Lead Sponsor: RMIT University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-03-04
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

A diagnosis of major depressive disorder, dysthymic disorder or an anxiety disorder where worry and rumination are prominent features. Each participant’s eligibility will be assessed using the depression and anxiety modules of the Structured Clinical Interview for DSM-IV-TR Axis I Disorders (Patient Edition, with Psychotic Screen; First, Gibbon, Spitzer, & Williams, 2007).

Exclusion Criteria

Individuals who meet the inclusion criteria but who have co-morbid psychosis, suicidal intent, Obsessive Compulsive Disorder, Post Traumatic Stress Disorder or an eating disorder will be excluded from participating in the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Depression, Anxiety and Stress Scales (DASS-21)[1. Baseline<br>2. Weekly during the intervention<br>3. Post-treatment<br>4. At 3 months follow-up<br>5. At 6 months follow-up];Penn State Worry Questionnaire (PSWQ)[1. Baseline<br>2. Weekly during the intervention<br>3. Post-treatment<br>4. At 3 months follow-up<br>5. At 6 months follow-up];Ruminative Thought Style Questionnaire (RTS)[1. Baseline<br>2. Weekly during the intervention<br>3. Post-treatment<br>4. At 3 months follow-up<br>5. At 6 months follow-up]

Secondary Outcome Measures

Name	Time	Method
Acceptance and Action Questionnaire-II (AAQ-II)[1. Baseline<br>2. Post-treatment<br>3. At 3 months follow-up<br>4. At 6 months follow-up];White Bear Suppression Inventory (WBSI)[1. Baseline<br>2. Post-treatment<br>3. At 3 months follow-up<br>4. At 6 months follow-up];Valued Living Questionnaire (VLQ)[1. Baseline<br>2. Post-treatment<br>3. At 3 months follow-up<br>4. At 6 months follow-up];Behavioural Activation for Depression Scale (BADS)[1. Baseline<br>2. Post-treatment<br>3. At 3 months follow-up<br>4. At 6 months follow-up];Sheehan Disability Scale[1. Baseline<br>2. Post-treatment<br>3. At 3 months follow-up<br>4. At 6 months follow-up];Mindful Attention and Awareness Scale (MAAS)[1. Baseline<br>2. Post-treatment<br>3. At 3 months follow-up<br>4. At 6 months follow-up];Automatic Thoughts Questionnaire (ATQ)[1. Baseline<br>2. Post-treatment<br>3. At 3 months follow-up<br>4. At 6 months follow-up]